AIIMS Delhi to start screening children for Covaxin trials from Monday

The All India Institute of Medical Sciences (AIIMS), Delhi, will start screening children for clinical trials of indigenous home-grown Covid-19 vaccineBharat Biotech‘s Covaxin, from Monday, sources said.

AIIMS Delhi will be starting clinical trials after AIIMS Patna which started the trials recently on children aged between 12 and 18 years old.

After getting permission from the Drugs Controller General of India (DCGI), AIIMS, Delhi is now starting the screening for clinical trials before starting the trials.

To grant the permission of trials, DCGI’s approval was followed by a recommendation on May 12 by a Subject Expert Committee (SEC).

  • Related Posts

    • Pharma
    • June 25, 2025
    • 89 views
    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    A major face-off is expected in India’s growing anti-obesity treatment market, as Danish pharma giant Novo Nordisk rolled out its blockbuster weight-loss drug Wegovy on Tuesday, just a month after…

    • Pharma
    • June 25, 2025
    • 110 views
    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Hyderabad:  Aurobindo Pharma Ltd wholly owned step-down subsidiary CuraTeQ Biologics has obtained marketing authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, its pegylated filgrastim biosimilar…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Novo Nordisk launches blockbuster weight-loss drug Wegovy in India; Check price, dosage and other details

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Aurobindo Pharma arm gets marketing authorization in UK for Dyrupeg

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Sun Pharma’s European partner withdraws application for skin cancer treatment therapy

    Glenmark Pharma launches TEVIMBRA in India

    Glenmark Pharma launches TEVIMBRA in India